Physician profile
Vi Tran
NPI 1649731274
$1,259.50
in general payments reported to CMS, 2019-2025
13 companies · $57.78 in 2025
The $57.78 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $22.83 · 2021: $294 · 2022: $681 · 2023: $204 · 2025: $57.78.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $150 · Food and Beverage: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $150.00 |
| Food and Beverage | $112.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $258.49 | 2022-2023 | Tysabri, Vumerity |
| Abbvie INC. | $250.57 | 2022-2025 | Botox |
| Alexion Pharmaceuticals, INC. | $223.51 | 2021-2022 | |
| Acorda Therapeutics, INC | $181.87 | 2021-2022 | |
| Tanabe Pharma America, INC. | $92.12 | 2022 | |
| Jazz Pharmaceuticals INC. | $75.56 | 2022 | |
| Csl Behring | $61.31 | 2020-2022 | |
| Terumo Medical Corporation | $26.60 | 2025 | R2p Misago |
| Avion Pharmaceuticals | $20.11 | 2022 | |
| Emd Serono, INC. | $19.75 | 2022 | |
| Acadia Pharmaceuticals INC | $19.63 | 2022 | |
| Allergan, INC. | $15.36 | 2022 | |
| Lilly USA, LLC | $14.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vi Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.